Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/AVXL-Info-Request-Form-1048. There is no cost or obligation to you.
According to the complaint, Anavex issued misleading statements and failed to disclose that the Company had used a paid stock promoter to artificially inflate the Company’s share price.
On December 29, 2015, Anavex disclosed that it had received a subpoena from the SEC on December 22, 2015. Anavex stated, in part, that “[t]he Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares.” Then on December 30, 2015, Seeking Alpha published a report entitled “Anavex: A Regulatory Target Damaged By Incriminating Evidence.” On this news, Anavex stock fell $0.78, or 12.42%, to close at $5.50 per share.
If you suffered a loss in Anavex Life Sciences you have until February 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/AVXL-Info-Request-Form-1048.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
